Business
Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025
Record Revenue: Total revenues, net of excise taxes increased to $27.3 million in Q3 2025,...
About this update from Cannara Biotech, Inc.
[{"type":"text","content":"Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025\n\n\n\n\n\n Record Revenue:\n \n Total revenues, net of excise taxes increased to $27.3 million in Q3 2025, representing a 40% increase over the prior year period.\n \n\n\n Record Profitability:\n \n Gross profit before fair value adjustments rose to $12.1 million in Q3 2025, representing a 110% increase over the prior year period. Gross margin before fair value adjustments rose to 44% in Q3 2025, from 29% in the prior year period.\n \n\n\n Record Adjusted EBITDA and Adjusted EBITDA Margin:\n \n Delivered seventeenth consecutive quarter of positive Adjusted EBITDA, which increased to a record high of $7.6 million in Q3 2025\n \n 1\n \n , representing a 173% increase over the prior year period. Delivered Adjusted EBITDA margin rose to 28% in Q3 2025, from 14% in the prior year period.\n \n\n\n Record Operating and Free Cash Flow:\n \n Delivered $13.9 million of operating cash flow and $11.7 million of free cash flow\n \n 1\n \n in Q3 2025, representing a 221% and 841% respective increase over the prior year period.\n \n\n\n Yield Improvement:\n \n Extensive research and development on optimizing cultivation procedures has driven a 26% yield improvement across Cannara’s facilities, increasing current annual capacity from 39,500 kg to 50,000 kg — allowing the Company to achieve its Fiscal 2026 cultivation target a full year ahead of schedule without additional capital expenditures.\n \n\n\n Quebec Vape Launch:\n \n Received 5 accepted SKUs, pending final procedural steps, for the Quebec provincial vape category launch, representing 20% of all accepted in-store SKUs by the SQDC.\n \n\n\n Reduced Interest Rate:\n \n Lowered interest rate on BMO credit facility by 50 basis points and a further 25 basis points subsequent to quarter-end. Cannara’s cost of debt on its credit facility is now below 6%.\n \n\n\n\n\n All financial results are reported in Canadian dollars, unless otherwise stated.\n \n\n\n MONTREAL, July 28, 2025 (GLOBE NEWSWIRE) --\n \n\n Cannara Biotech Inc.\n \n\n (“\n \n Cannara\n \n ”, “the\n \n Company\n \n ”, “\n \n us\n \n ” or “\n \n we\n \n ”) (\n \n\n TSXV: LOVE\n \n\n ) (\n \n\n OTCQB: LOVFF\n \n\n ) (\n \n\n FRA: 8CB0\n \n\n ), a vertic...